Skip to content
Open access

Clinical Risk Factors for Advanced Fibrosis in Pathology-Proven Steatotic Liver Disease: Emphasis on Nonelder Subjects.

Oct 2026 · Journal of Gastroenterology and Hepatology · 0 citations · 32 references
Medicine

TL;DR

Older age, alcohol, T2DM, chronic HBV infection, and obesity were associated with advanced fibrosis, and risk factors and noninvasive score performance varied in nonelder subjects.

Abstract

Background

AND

Aim

Steatotic liver disease (SLD) may lead to advanced liver diseases. We aimed to identify clinical risk factors for advanced fibrosis in pathology-proven SLD patients in a hepatitis B virus (HBV) endemic population, with emphasis on nonelder subjects.

Methods

Adult SLD patients diagnosed via pathology at National Taiwan University Hospital between June 2009 and December 2023 were recruited. Advanced fibrosis was defined as F2 to F4 fibrosis. Patients were stratified by age (< 50 years defined as nonelder), metabolic dysfunction-associated steatotic liver disease (MASLD), and HBV infection. Clinical risk factors for advanced fibrosis and at-risk steatohepatitis were investigated, and the predictive performance of noninvasive scores was examined.

Results

Among 223 pathology-proven SLD patients, older age (odds ratio [OR]: 1.04), alcohol consumption (OR: 5.77), type 2 diabetes mellitus (T2DM) (OR: 2.13), chronic HBV infection (OR: 2.52), and obesity (OR: 2.64) were independent risk factors for advanced fibrosis. In the nonelder subgroup, older age (OR: 1.10) and obesity (OR: 3.75) were significant. In the MASLD subgroup, older age (OR: 1.04), hypertension (OR: 2.31), T2DM (OR: 3.07), and chronic HBV infection (OR: 3.59) remained significant. Obesity (OR: 4.14) was a significant risk factor for at-risk steatohepatitis in the nonelder subgroup. NAFLD fibrosis score had the highest AUROC (0.724) for advanced fibrosis in the entire cohort, while FIB-4 performed best in nonelder subjects.

Conclusions

Older age, alcohol, T2DM, chronic HBV infection, and obesity were associated with advanced fibrosis. Risk factors and noninvasive score performance varied in nonelder subjects.

Read PDF

Similar papers

Open access Oct 2026

CO-53 | LIVER FIBROSIS, STEATOSIS AND SUBCLINICAL ATHEROSCLEROSIS IN PATIENTS WITH HEMOPHILIA: A CROSS-SECTIONAL STUDY

Background and Aims. Metabolic dysfunction–associated steatotic liver disease (MASLD) is an emerging cardiovascular risk factor. As patients with hemophilia (PWH) age and develop metabolic comorbidities, cardiovascular disease is becoming increasingly relevant despite their inherited bleeding tendency. In addition, liv...

C. Simion · 0 citations
Sep 2026

Risk Factors and Definition of Younger-Onset Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Cirrhosis.

BACKGROUND & AIMS Cirrhosis from metabolic dysfunction-associated steatotic liver disease (MASLD) usually develops with advancing age, yet a subset of patients presents at younger ages. We examined genetic and metabolic factors associated with younger-onset MASLD cirrhosis. APPROACH AND RESULTS Adults with biopsy-pro...

Veeral H. Ajmera, Linus Schwantes-An, Luis Antonio Díaz et al. · 0 citations
Open access Nov 2026

Porto-sinusoidal vascular disorder-type lesions in patients with early fibrotic stages of metabolic dysfunction-associated steatotic liver disease.

BACKGROUND AND OBJECTIVE Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rising cause of chronic liver disease. Liver stiffness measurement (LSM) to assess disease stage is gaining popularity but can demonstrate heterogeneous results in clinical practice. Moreover, portal hypertension may develop...

Diederick J. van Doorn, L. Schoenmakers, S. de Jager et al. · 0 citations
Review Open access Oct 2026

Review Article: Fibrosis-4 Index in Steatotic Liver Disease-Past, Present and Future.

In the precision therapy era, FIB-4 remains a scalable front-door test but should not serve as a stand-alone selector for drug eligibility; confirmatory staging is required to identify F2-F3 disease and exclude cirrhosis.

K. Soni, V. Jahagirdar, Omar Albhaisi et al. · 0 citations
Open access Oct 2026

Screening for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes patients using the fibrosis-4 score in medina-retrospective study

The findings endorse the need for screening for liver fibrosis in T2DM patients, particularly those at increased risk, and suggest early detection and appropriate management are essential to prevent progression to advanced liver disease.

M. Almohammadi, Z. E. Alsadi, A. B. Alenezi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.